SEARCH

SEARCH BY CITATION

References

  • 1
    Howard VJ, McClure LA, Meschia JF, et al. High prevalence of stroke symptoms among persons without a diagnosis of stroke or transient ischemic attack in a general population: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Arch Intern Med. 2006;166(18):19521958.
  • 2
    Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16(3):280285.
  • 3
    Chambless LE, Shahar E, Sharrett AR, et al. Association of transient ischemic attack/stroke symptoms assessed by standardized questionnaire and algorithm with cerebrovascular risk factors and carotid artery wall thickness. The ARIC Study, 1987–1989. Am J Epidemiol. 1996;144(9):857866.
  • 4
    Chambless LE, Toole JF, Nieto FJ, et al. Association between symptoms reported in a population questionnaire and future ischemic stroke: the ARIC study. Neuroepidemiology. 2004;23(1-2):3337.
  • 5
    Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34(5):11261129.
  • 6
    Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA. 1981;245(12):12251229.
  • 7
    O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet. 2010;376(9735):112123.
  • 8
    Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19(4):357362.
  • 9
    World Health Orgainzation. Adherence To Long-Term Therapies: Evidence For Action. Geneva, Switzerland: World Health Organization; 2003.
  • 10
    Elliott WJ. Compliance—and improving it—in hypertension. Manag Care. 2003;12(8 Suppl Hypertension):5661.
  • 11
    Hyre AD, Krousel-Wood MA, Muntner P, et al. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich). 2007;9(3):179186.
  • 12
    Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348354.
  • 13
    Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15(3):9096.
  • 14
    Muntner P, Judd SE, Krousel-Wood M, et al. Low medication adherence and hypertension control among adults with CKD: data From the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis. 2010;56(3):447457.
  • 15
    Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15(1):5966.
  • 16
    Krousel-Wood MA, Muntner P, Islam T, et al. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93(3):753769.
  • 17
    DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794811.
  • 18
    Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135143.
  • 19
    Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385401.
  • 20
    Callahan CM, Unverzagt FW, Hui SL, et al. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40(9):771781.
  • 21
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):25602572.
  • 22
    Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604612.
  • 23
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):6774.
  • 24
    Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38(9):13631368.
  • 25
    Meschia JF, Brott TG, Chukwudelunzu FE, et al. Verifying the stroke-free phenotype by structured telephone interview. Stroke. 2000;31(5):10761080.
  • 26
    Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination. Stroke. 2001;32(10):22322236.
  • 27
    Meschia JF, Lojacono MA, Miller MJ, et al. Reliability of the questionnaire for verifying stroke-free status. Cerebrovasc Dis. 2004;17(2-3):218223.
  • 28
    Allison P. Estimating Parametric Regression Models with PROC LIFEREG. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Publishing; 2008:61110.
  • 29
    Finkelstein DM. A proportional hazards model for interval-censored failure time data. Biometrics. 1986;42(4):845854.
  • 30
    Howard G, Safford MM, Meschia JF, et al. Stroke symptoms in individuals reporting no prior stroke or transient ischemic attack are associated with a decrease in indices of mental and physical functioning. Stroke. 2007;38(9):24462452.
  • 31
    Muntner P, DeSalvo KB, Wildman RP, et al. Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiol. 2006;163(10):913920.
  • 32
    Patient behavior for blood pressure control. Guidelines for professionals. JAMA. 1979;241(23):25342537.
  • 33
    Alderman MH. Barriers to blood pressure control. Am J Hypertens. 1999;12(12 Pt 1-2):12681269.
  • 34
    Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: HaynesRB, TaylorDW, SackettDL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press; 1992:1122.
  • 35
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303(20):20432050.
  • 36
    DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200209.
  • 37
    Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.
  • 38
    Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213220.
  • 39
    Bailey JE, Wan JY, Tang J, et al. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010;25(6):495503.
  • 40
    Krousel-Wood M, Hyre A, Muntner P, et al. Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr Opin Cardiol. 2005;20(4):296300.
  • 41
    Maddox TM, Ross C, Tavel HM, et al. Blood pressure trajectories and associations with treatment intensification, medication adherence, and outcomes among newly diagnosed coronary artery disease patients. Circ Cardiovasc Qual Outcomes. 2010;3(4):3747.